Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in accordance with supplementary material requirements and will disclose key information as per legal obligations [1] Group 1: Company Developments - The company is actively contributing to the macroeconomic strategy addressing population aging, focusing on traditional Chinese medicine [1] - Kangyuan has core products targeting health needs of the elderly, including treatments for cardiovascular diseases and bone injuries, such as Ginkgo Biloba Diterpene Injection and Tian Shu Capsules [1] - The company is also developing treatments for Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with related products entering clinical stages [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported revenue of 2.343 billion yuan, a year-on-year decrease of 24.59% (adjusted) [1] - The net profit attributable to the parent company was 200 million yuan, reflecting a year-on-year decline of 35.63% [1]

Core Viewpoint - Kangyuan Pharmaceutical has initiated clinical trials for Longqi Capsules in response to supplementary material requirements and will disclose key information regarding trial progress and review results in accordance with legal regulations [1] Group 1: Company Initiatives - The company is actively aligning with the macroeconomic strategy of an aging population, leveraging its strengths in traditional Chinese medicine to address health needs of the elderly [1] - Kangyuan Pharmaceutical has core products targeting age-related diseases, including Ginkgo Biloba Diterpene Injection, Tienshu Capsules/Tablets, and Tongsemai Capsules/Tablets [1] Group 2: Research and Development Focus - The company is expanding its research and development efforts in areas related to aging, including Alzheimer's disease, sleep disorders, and chronic obstructive pulmonary disease, with relevant products already in clinical stages [1]

Core Viewpoint - Kangyuan Pharmaceutical has recently received a drug registration certificate for Xiebaisan Granules from the National Medical Products Administration [2] Company Summary - Kangyuan Pharmaceutical announced the receipt of the drug registration certificate for Xiebaisan Granules on December 12 [2]

Core Viewpoint - Kangyuan Pharmaceutical (600557) has recently received a drug registration certificate for Xiebaisan granules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product aimed at treating pediatric cough and asthma due to lung heat [1] Group 1 - The drug Xiebaisan is indicated for clearing lung heat and alleviating cough and asthma symptoms in children [1] - The approval of the drug registration certificate represents a milestone for Kangyuan Pharmaceutical, potentially enhancing its product portfolio and market presence [1]

证券简称：康缘药业 证券代码：600557 公告编号：2025-046 江苏康缘药业股份有限公司 关于获得泻白散颗粒药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理 局签发的泻白散颗粒《药品注册证书》。按照《上海证券交易所上市公司自律监管 指引第 3 号——行业信息披露》的相关要求，现将药品相关情况公告如下： 一、药品基本情况 药品通用名称：泻白散颗粒 主要成份：炒桑白皮、地骨皮（焙）、炒甘草、粳米 剂型：颗粒剂 功能主治：清泻肺热，止咳平喘。用于小儿肺热咳喘证。症见气喘咳嗽，皮肤 蒸热，日晡尤甚，舌红苔黄，脉细数。 药品有效期：18 个月 处方药/非处方药：处方药 药品注册标准编号：YBZ00832025 药品批准文号：国药准字 C20250016 1 规格：每袋相当于饮片 8.20g 注册分类：中药 3.1 类 是否独家：是 药品生产企业：江苏康缘药业股份有限公司 二、药品研发及相关市场情况 泻白散出自宋·钱乙《小儿药证直诀》，由桑白 ...

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received the drug registration certificate for Xiebaisan Granules from the National Medical Products Administration, which is expected to enhance the clinical application of traditional Chinese medicine and improve the company's market competitiveness in pediatric medication [1] Group 1: Product Approval - The drug's generic name is Xiebaisan Granules, with registration standard number YBZ00832025 and approval number Guoyao Zhunzi C20250016 [1] - Xiebaisan is effective in clearing lung heat and alleviating cough and asthma, specifically for pediatric patients with symptoms such as wheezing and cough [1] Group 2: Clinical Application - Xiebaisan has a long history of clinical use and is recognized for its efficacy and low adverse reactions, which supports its broader application in clinical settings [1] - The approval of Xiebaisan Granules is expected to promote the use of classical formulas in clinical practice, enhancing the level of traditional Chinese medicine services [1] Group 3: Market Impact - Pediatric medication is a key area for the company, and the approval of Xiebaisan Granules enriches its pediatric product lineup [1] - This development is anticipated to strengthen the company's market competitiveness and brand influence in the pediatric sector, laying a solid foundation for sustained profitability [1]

Core Viewpoint - Kangyuan Pharmaceutical has received a drug registration certificate for Xiebaisan Granules from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Product Details - The drug's generic name is Xiebaisan Granules, with main ingredients including fried mulberry bark, prepared lycium bark, fried licorice, and glutinous rice [1] - The dosage form is granules, with a specification equivalent to 8.20g of decoction pieces per bag [1] - The registration classification is Traditional Chinese Medicine Class 3.1, and the drug has a shelf life of 18 months, classified as a prescription drug [1]

（编辑 任世碧） 证券日报网讯 12月11日晚间，康缘药业发布公告称，公司董事会于近日收到公司董事兼财务总监江锁 成先生、副总经理鲜飞鹏先生提交的辞任报告。江锁成先生因工作调整原因申请辞去董事兼战略委员会 委员、财务总监职务，辞去上述职务后，其仍继续在公司任职。鲜飞鹏先生因个人原因申请辞去副总经 理职务，其辞职后不再担任公司及控股子公司的任何职务。公司已于2025年12月11日召开第八届董事会 第二十二次会议，审议通过了《关于聘任财务总监的议案》，聘任李清先生为公司财务总监。 ...

Core Viewpoint - Kangyuan Pharmaceutical (600557) announced changes in its executive team, including the resignation of Jiang Suocheng as CFO and board member, and the appointment of Li Qing as the new CFO [1] Group 1: Executive Changes - Jiang Suocheng resigned from his positions as a board member, strategic committee member, and CFO due to work adjustments, but will continue to work at the company [1] - Xian Feipeng resigned from his position as Deputy General Manager for personal reasons and will not hold any positions in the company or its subsidiaries after his resignation [1] - The company held a board meeting to appoint Li Qing as the new CFO, effective from the date of board approval until the end of the current board's term [1]

江苏康缘药业股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为规范江苏康缘药业股份有限公司（以下简称"公司"）的内幕信 息管理，加强内幕信息保密工作，维护信息披露公平性，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上海证券交 易所股票上市规则》等法律法规及《江苏康缘药业股份有限公司章程》（以下简 称《公司章程》）的有关规定，结合公司实际情况，特制定本制度。 第七条 本制度所指内幕信息是指涉及公司的经营、财务或者对该发行人证 券的市场价格有重大影响的尚未公开的信息。 发生可能对公司的股票交易价格产生较大影响的重大事件包括： （一）公司的经营方针和经营范围的重大变化； （二）公司的重大投资行为，公司在一年内购买、出售重大资产超过公司资 产总额百分之三十，或者公司营业用主要资产的抵押、质押、出售或者报废一次 超过该资产的百分之三十； 第二条 公司内幕信息管理工作由董事会统一领导和管理，公司董事会应当 按照相关规则要求及时登记和报送内幕信息知情人档案，并保证内幕信息知情人 档案真实、准确和完整，董事长为主要责任人。董事会秘书组织实施，负责办理 公司内幕信息知情人 ...